Malaysian Genomics Resource
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services worldwide. Its flagship product, Dtect genetic screening tests which inspects DNA for markers associated with genetic variations that influence various biological processes. The company also offers genome sequencing services for humans, animals, pla… Read more
Malaysian Genomics Resource (0155) - Total Assets
Latest total assets as of September 2025: RM20.70 Million MYR
Based on the latest financial reports, Malaysian Genomics Resource (0155) holds total assets worth RM20.70 Million MYR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Malaysian Genomics Resource - Total Assets Trend (2015–2025)
This chart illustrates how Malaysian Genomics Resource’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Malaysian Genomics Resource - Asset Composition Analysis
Current Asset Composition (June 2025)
Malaysian Genomics Resource's total assets of RM20.70 Million consist of 51.8% current assets and 48.2% non-current assets.
| Asset Category | Amount (MYR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RM0.00 | 1.2% |
| Accounts Receivable | RM10.15 Million | 45.4% |
| Inventory | RM936.53K | 4.2% |
| Property, Plant & Equipment | RM4.39 Million | 19.6% |
| Intangible Assets | RM3.88 Million | 17.4% |
| Goodwill | RM0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Malaysian Genomics Resource's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Malaysian Genomics Resource's current assets represent 51.8% of total assets in 2025, an increase from 39.7% in 2015.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2025, up from 0.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 11.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 45.4% of total assets.
Malaysian Genomics Resource Competitors by Total Assets
Key competitors of Malaysian Genomics Resource based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
Optipharm.CO.LTD
KQ:153710
|
Korea | ₩42.32 Billion |
|
Bionet
TWO:1784
|
Taiwan | NT$3.10 Billion |
|
Cytogen Inc
KQ:217330
|
Korea | ₩67.68 Billion |
Malaysian Genomics Resource - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Malaysian Genomics Resource generates 0.25x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Malaysian Genomics Resource is currently not profitable relative to its asset base.
Malaysian Genomics Resource - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.56 | 3.50 | 9.76 |
| Quick Ratio | 3.39 | 3.25 | 9.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | RM7.91 Million | RM 8.36 Million | RM 7.15 Million |
Malaysian Genomics Resource - Advanced Valuation Insights
This section examines the relationship between Malaysian Genomics Resource's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.54 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -13.0% |
| Total Assets | RM22.36 Million |
| Market Capitalization | $1.99 Million USD |
Valuation Analysis
Below Book Valuation: The market values Malaysian Genomics Resource's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Malaysian Genomics Resource's assets decreased by 13.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Malaysian Genomics Resource (2015–2025)
The table below shows the annual total assets of Malaysian Genomics Resource from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | RM22.36 Million | -13.03% |
| 2024-06-30 | RM25.70 Million | -16.74% |
| 2023-06-30 | RM30.87 Million | -26.30% |
| 2022-06-30 | RM41.89 Million | +83.86% |
| 2021-06-30 | RM22.78 Million | +105.51% |
| 2020-06-30 | RM11.09 Million | -70.04% |
| 2019-06-30 | RM37.00 Million | -9.39% |
| 2018-06-30 | RM40.84 Million | +8.05% |
| 2017-06-30 | RM37.80 Million | +76.08% |
| 2016-06-30 | RM21.47 Million | -1.16% |
| 2015-06-30 | RM21.72 Million | -- |